GlassScriptPhysician profile
John F Carey
NPI 1629038534
$2,925.62
in general payments reported to CMS, 2019-2025
27 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $146 · 2021: $391 · 2022: $687 · 2023: $475 · 2024: $306 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $389.76 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $287.25 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $208.91 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $198.73 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.06 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $187.36 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Boston Scientific Corporation | $178.95 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.04 | 2019-2021 | |
| Pfizer INC. | $170.16 | 2019-2022 | |
| Amarin Pharma, INC. | $137.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $129.57 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $118.45 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $90.25 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $79.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.79 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60.70 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $41.36 | 2019-2021 | |
| Abbott Laboratories | $41.21 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $27.69 | 2022 | |
| Leo Pharma INC. | $25.02 | 2025 | Adbry |
| Eisai INC. | $22.14 | 2024 | |
| Sumitomo Pharma America, INC. | $19.56 | 2025 | Gemtesa |
| Opko Pharmaceuticals, LLC | $19.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.22 | 2021 | |
| Esperion Therapeutics, INC. | $14.84 | 2021 | |
| Clarus Therapeutics INC. | $14.79 | 2021 | |
| Sanofi Pasteur INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.